-transparent.png){kind=logo}
A randomized double-blind trial of hyperbaric oxygen (2 atmospheres absolute for 20 sessions of 90 minutes, over a period of one month) demonstrated no advantage over a placebo gas mixture in the treatment of multiple sclerosis. Of 41 patients completing the trial, 21 had been treated with oxygen, eight of whom reported improvement (two confirmed objectively). Of 20 patients in the placebo group, seven claimed improvement (four confirmed objectively). Even when patients with mild disease were considered separately, or when functional systems were assessed individually, no benefit could be shown to result from hyperbaric oxygen therapy.
Related Publications
J Wood, and
R Stell, and
I Unsworth, and
J W Lance, and
N Skuse
February 1986,
British medical journal (Clinical research ed.),
J Wood, and
R Stell, and
I Unsworth, and
J W Lance, and
N Skuse
November 1987,
Journal of neurology, neurosurgery, and psychiatry,
J Wood, and
R Stell, and
I Unsworth, and
J W Lance, and
N Skuse
January 1983,
The New England journal of medicine,
J Wood, and
R Stell, and
I Unsworth, and
J W Lance, and
N Skuse
February 1985,
Lancet (London, England),
J Wood, and
R Stell, and
I Unsworth, and
J W Lance, and
N Skuse
January 1986,
Revue neurologique,
J Wood, and
R Stell, and
I Unsworth, and
J W Lance, and
N Skuse
July 1986,
Neurology,
J Wood, and
R Stell, and
I Unsworth, and
J W Lance, and
N Skuse
September 1986,
Presse medicale (Paris, France : 1983),
J Wood, and
R Stell, and
I Unsworth, and
J W Lance, and
N Skuse
January 1987,
The New Zealand medical journal,
J Wood, and
R Stell, and
I Unsworth, and
J W Lance, and
N Skuse
May 1986,
Harefuah,
J Wood, and
R Stell, and
I Unsworth, and
J W Lance, and
N Skuse
September 1985,
The Medical journal of Australia,
